8-K: Zivo Bioscience Restructures Debt Through Promissory Notes

Zivo Bioscience has entered into debt settlement agreements with three creditors, issuing promissory notes totaling $277,254.38 to restructure existing debt.

Summary

• Zivo Bioscience has restructured some of its debt by entering into debt settlement agreements with Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund.
• The company issued unsecured promissory notes to each creditor in exchange for settling existing debt.
• The total principal amount of the notes is $277,254.38.
• Howard Shapiro received a note for $185,497.12, Merger Masters Pension Fund received a note for $40,331.51, and Financial Trading Consultants Pension Fund received a note for $51,425.75.
• The notes are payable in 24 equal monthly installments starting November 30, 2024, and bear an annual interest rate of 1.0%.
• The notes can be prepaid at any time without penalty.
• The notes are subject to customary events of default, which could trigger immediate payment of the outstanding principal balance.

Sentiment

Score: 5

Explanation: The document describes a debt restructuring, which is a neutral event. It is neither particularly positive nor negative, but rather a necessary step for the company to manage its finances.

Positives

• The debt restructuring provides Zivo Bioscience with a defined repayment schedule.
• The 1.0% interest rate on the notes is relatively low.
• The ability to prepay the notes without penalty offers financial flexibility.

Negatives

• The company is taking on new debt obligations.
• Default on the notes could trigger immediate repayment of the full principal amount.

Risks

• The company's ability to meet the monthly payment obligations is dependent on its financial performance.
• A default on the notes could have a significant negative impact on the company's financial position.
• The company's financial health is not explicitly stated in the document, so the ability to repay the debt is unknown.

Future Outlook

The company will need to make 24 monthly payments on the notes starting November 30, 2024.

Industry Context

Debt restructuring is a common practice for companies seeking to manage their financial obligations, especially for smaller companies with limited access to capital markets.

Comparison to Industry Standards

• The interest rate of 1.0% is relatively low compared to typical rates for unsecured debt, suggesting the creditors may have a strong relationship with the company or a high level of confidence in its future.
• The 24-month repayment term is a fairly standard duration for short-term debt restructuring agreements.
• It is difficult to compare this to other companies without knowing the specific financial situation of Zivo Bioscience and the terms of their previous debt.

Stakeholder Impact

• Shareholders may view the debt restructuring as a positive step towards financial stability.
• Creditors have agreed to a structured repayment plan.

Next Steps

• Zivo Bioscience will begin making monthly payments on the promissory notes starting November 30, 2024.

Key Dates

Keywords

debt settlement, promissory notes, debt restructuring, financial obligation, Zivo Bioscience